Histopathologic manifestations of drug-induced hepatotoxicity

Clinics in Liver Disease

Volumn 17, Issue 4, 2013, Pages 547-564

  Zhang, Xuchen ^a   Ouyang, Jie ^b   Thung, Swan N ^c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FLORIDA HOSPITAL   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Drug induced hepatotoxicity; Drugs; Liver injury; Pathology

Indexed keywords

AMINOSALICYLIC ACID; AMIODARONE; AMOXICILLIN PLUS CLAVULANIC ACID; ATORVASTATIN; BENTAZEPAM; CARBON TETRACHLORIDE; CLOMETACIN; COCAINE; DAPSONE; DIAMORPHINE; ENALAPRIL; ERYTHROMYCIN; FERROUS SULFATE; HALOTHANE; INFLIXIMAB; ISONIAZID; METHOTREXATE; METHYLDOPA; MINOCYCLINE; NITROFURANTOIN; ORAL CONTRACEPTIVE AGENT; PARACETAMOL; PHENOTHIAZINE; PHENYTOIN; SULFONAMIDE; THORIUM DIOXIDE; TIENILIC ACID; UNINDEXED DRUG; VALPROIC ACID; VINYL CHLORIDE;

AMANITA PHALLOIDES; AUTOIMMUNE HEPATITIS; CELL INCLUSION; CENTRILOBULAR NECROSIS; CHOLESTATIC HEPATITIS; CHRONIC HEPATITIS; CHRONIC LIVER DISEASE; CLINICAL FEATURE; DRUG INDUCED CANCER; FATTY LIVER; GRANULOMATOUS HEPATITIS; HUMAN; LIPIDOSIS; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CELL DAMAGE; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER GRANULOMA; LIVER HISTOLOGY; LIVER VEIN OBSTRUCTION; LIVER VENOOCCLUSIVE DISEASE; NONALCOHOLIC FATTY LIVER; PELIOSIS HEPATIS; RETINOL INTOXICATION; REVIEW; SPOTTY CELL DEATH; TOXIC HEPATITIS;

DRUG-INDUCED HEPATOTOXICITY; DRUGS; LIVER INJURY; PATHOLOGY;

ASPIRIN; CELL DEATH; DRUG-INDUCED LIVER INJURY; HEPATOCYTES; HUMANS; IMMUNOHISTOCHEMISTRY;

EID: 84884927979     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2013.07.004     Document Type: Review

References (115)

1. Lee W.M. Drug-induced hepatotoxicity. NEngl J Med 2003, 349:474-485.
2. Bleibel W., Kim S., D'Silva K., et al. Drug-induced liver injury: review article. Dig Dis Sci 2007, 52:2463-2471.
3. Tujios S., Fontana R.J. Mechanisms of drug-induced liver injury: from bedside to bench. Nat Rev Gastroenterol Hepatol 2011, 8:202-211.
4. Davern T.J. Drug-induced liver disease. Clin Liver Dis 2012, 16:231-245.
5. Kleiner D.E. The pathology of drug-induced liver injury. Semin Liver Dis 2009, 29:364-372.
6. Andrade R.J., Robles M., Fernandez-Castaner A., et al. Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists. World J Gastroenterol 2007, 13:329-340.
7. Gan T.E., Van der Weyden M.B. Dapsone-induced infectious mononucleosis-like syndrome. Med J Aust 1982, 1:350-351.
8. Spigset O. Drug-induced hepatic injuries. Tidsskr Nor Laegeforen 1998, 118:2805-2808. [in Norwegian].
9. Dalton H.R., Fellows H.J., Stableforth W., et al. The role of hepatitis E virus testing in drug-induced liver injury. Aliment Pharmacol Ther 2007, 26:1429-1435.
10. Davern T.J., Chalasani N., Fontana R.J., et al. Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology 2011, 141:1665-1672.e1-9.
11. Lee W.M. Drug-induced hepatotoxicity. NEngl J Med 1995, 333:1118-1127.
12. Bjornsson E., Kalaitzakis E., Av Klinteberg V., et al. Long-term follow-up of patients with mild to moderate drug-induced liver injury. Aliment Pharmacol Ther 2007, 26:79-85.
13. Andrade R.J., Lucena M.I., Kaplowitz N., et al. Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry. Hepatology 2006, 44:1581-1588.
14. Hou F.Q., Zeng Z., Wang G.Q. Hospital admissions for drug-induced liver injury: clinical features, therapy, and outcomes. Cell Biochem Biophys 2012, 64:77-83.
15. Bunchorntavakul C., Reddy K.R. Herbal and dietary supplement hepatotoxicity. Aliment Pharmacol Ther 2013, 37:3-17.
16. Efe C. Drug induced autoimmune hepatitis and TNF-alpha blocking agents: is there a real relationship?. Autoimmun Rev 2013, 12(3):337-339.
17. Czaja A.J. Drug-induced autoimmune-like hepatitis. Dig Dis Sci 2011, 56:958-976.
18. Suzuki A., Brunt E.M., Kleiner D.E., et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology 2011, 54:931-939.
19. Lewis J.H. Diagnosis: liver biopsy differentiates DILI from autoimmune hepatitis. Nat Rev Gastroenterol Hepatol 2011, 8:540-542.
20. Ramachandran R., Kakar S. Histological patterns in drug-induced liver disease. JClin Pathol 2009, 62:481-492.
21. Yoshikado T., Takada T., Yamamoto H., et al. Ticlopidine, a cholestatic liver injury-inducible drug, causes dysfunction of bile formation via diminished biliary secretion of phospholipids: involvement of biliary-excreted glutathione-conjugated ticlopidine metabolites. Mol Pharmacol 2013, 83(2):552-562.
22. Vilas-Boas F., Goncalves R., Sobrinho Simoes M., et al. Thalidomide-induced acute cholestatic hepatitis: case report and review of the literature. Gastroenterol Hepatol 2012, 35:560-566.
23. Studniarz M., Czubkowski P., Cielecka-Kuszyk J., et al. Amoxicillin/clavulanic acid-induced cholestatic liver injury after pediatric liver transplantation. Ann Transplant 2012, 17:128-131.
24. Ruiz Rebollo M.L., Aller De La Fuente R., Macho Conesa A., et al. Amoxicillin-induced cholestatic hepatitis. Gastroenterol Hepatol 2011, 34:474-477.
25. Stadlmann S., Portmann S., Tschopp S., et al. Venlafaxine-induced cholestatic hepatitis: case report and review of literature. Am J Surg Pathol 2012, 36:1724-1728.
26. Nojkov B., Signori C., Konda A., et al. Lenalidomide-associated hepatotoxicity-a case report and literature review. Anticancer Res 2012, 32:4117-4119.
27. Devarbhavi H. Antituberculous drug-induced liver injury: current perspective. Trop Gastroenterol 2011, 32:167-174.
28. Avelar-Escobar G., Mendez-Navarro J., Ortiz-Olvera N.X., et al. Hepatotoxicity associated with dietary energy supplements: use and abuse by young athletes. Ann Hepatol 2012, 11:564-569.
29. Palta R., Thobani S., Donovan J.A., et al. Prolonged cholestasis associated with benazepril therapy. Am J Gastroenterol 2009, 104:245-246.
30. Yeung E., Wong F.S., Wanless I.R., et al. Ramipril-associated hepatotoxicity. Arch Pathol Lab Med 2003, 127:1493-1497.
31. Alazmi W.M., McHenry L., Watkins J.L., et al. Chemotherapy-induced sclerosing cholangitis: long-term response to endoscopic therapy. JClin Gastroenterol 2006, 40:353-357.
32. Qu K., Liu C., Wu Q.F., et al. Sclerosing cholangitis after transcatheter arterial chemoembolization: a case report. Chin Med Sci J 2011, 26:190-193.
33. Siddique A., Kowdley K.V. Approach to a patient with elevated serum alkaline phosphatase. Clin Liver Dis 2012, 16:199-229.
34. Plessier A., Rautou P.E., Valla D.C. Management of hepatic vascular diseases. JHepatol 2012, 56(Suppl 1):S25-S38.
35. Elbl C., Terracciano L., Stallmach T.K., et al. Herbal drugs mimicking primary biliary cirrhosis. Praxis (Bern 1994) 2012, 101:195-198.
36. Nakayama S., Murashima N. Overlap syndrome of autoimmune hepatitis and primary biliary cirrhosis triggered by fluvastatin. Indian J Gastroenterol 2011, 30:97-99.
37. Macias F.M., Campos F.R., Salguero T.P., et al. Ductopenic hepatitis related to Enalapril. JHepatol 2003, 39:1091-1092.
38. Nakanuma Y., Tsuneyama K., Harada K. Pathology and pathogenesis of intrahepatic bile duct loss. JHepatobiliary Pancreat Surg 2001, 8:303-315.
39. Vuppalanchi R., Chalasani N., Saxena R. Restoration of bile ducts in drug-induced vanishing bile duct syndrome due to zonisamide. Am J Surg Pathol 2006, 30:1619-1623.
40. Kleiner D.E., Brunt E.M. Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis 2012, 32:3-13.
41. Khan A.Z., Morris-Stiff G., Makuuchi M. Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases. JHepatobiliary Pancreat Surg 2009, 16:137-144.
42. Tannapfel A., Reinacher-Schick A., Flott-Rahmel B. Steatohepatitis after chemotherapy for colorectal liver metastases (CASH). Pathologe 2011, 32:330-335.
43. Coash M., Forouhar F., Wu C.H., et al. Granulomatous liver diseases: a review. JFormos Med Assoc 2012, 111:3-13.
44. Turhan N., Kurt M., Ozderin Y.O., et al. Hepatic granulomas: a clinicopathologic analysis of 86 cases. Pathol Res Pract 2011, 207:359-365.
45. Gaya D.R., Thorburn D., Oien K.A., et al. Hepatic granulomas: a 10 year single centre experience. JClin Pathol 2003, 56:850-853.
46. Fiel M.I., Shukla D., Saraf N., et al. Development of hepatic granulomas in patients receiving pegylated interferon therapy for recurrent hepatitis C virus post liver transplantation. Transpl Infect Dis 2008, 10:184-189.
47. Farah M., Al Rashidi A., Owen D.A., et al. Granulomatous hepatitis associated with etanercept therapy. JRheumatol 2008, 35:349-351.
48. Braun M., Fraser G.M., Kunin M., et al. Mesalamine-induced granulomatous hepatitis. Am J Gastroenterol 1999, 94:1973-1974.
49. Ruiz-Valverde P., Zafon C., Segarra A., et al. Ticlopidine-induced granulomatous hepatitis. Ann Pharmacother 1995, 29:633-634.
50. Vial T., Descotes J. Drug-induced granulomatous hepatitis. Gastroenterol Clin Biol 1993, 17:H44-H48.
51. Flamm S.L. Granulomatous liver disease. Clin Liver Dis 2012, 16:387-396.
52. Trivalle C., Profit P., Bonnet B., et al. Liver lipogranulomas with log-term fever caused by paraffin oil. Gastroenterol Clin Biol 1991, 15:551-553.
53. Dincsoy H.P., Weesner R.E., MacGee J. Lipogranulomas in non-fatty human livers. A mineral oil induced environmental disease. Am J Clin Pathol 1982, 78:35-41.
54. Fleming K.A., Zimmerman H., Shubik P. Granulomas in the livers of humans and Fischer rats associated with the ingestion of mineral hydrocarbons: a comparison. Regul Toxicol Pharmacol 1998, 27:75-81.
55. Zhu H., Bodenheimer H.C., Clain D.J., et al. Hepatic lipogranulomas in patients with chronic liver disease: association with hepatitis C and fatty liver disease. World J Gastroenterol 2010, 16:5065-5069.
56. Villamil-Cajoto I., Jove M.J., Serrano M., et al. Granulomatous hepatitis due to Mycobacterium complex following Bacillus Calmette-Guérin intravesical instillation. Enferm Infecc Microbiol Clin 2010, 28:759-761. [author reply: 761-2].
57. Stricker B.H., Blok A.P., Babany G., et al. Fibrin ring granulomas and allopurinol. Gastroenterology 1989, 96:1199-1203.
58. Khanlari B., Bodmer M., Terracciano L., et al. Hepatitis with fibrin-ring granulomas. Infection 2008, 36:381-383.
59. Tjwa M., De Hertogh G., Neuville B., et al. Hepatic fibrin-ring granulomas in granulomatous hepatitis: report of four cases and review of the literature. Acta Clin Belg 2001, 56:341-348.
60. Rubbia-Brandt L. Sinusoidal obstruction syndrome. Clin Liver Dis 2010, 14:651-668.
61. Sebagh M., Azoulay D., Roche B., et al. Significance of isolated hepatic veno-occlusive disease/sinusoidal obstruction syndrome after liver transplantation. Liver Transpl 2011, 17:798-808.
62. Robinson S.M., White S.A. Hepatic sinusoidal obstruction syndrome reduces the effect of oxaliplatin in colorectal liver metastases. Histopathology 2012, 61:1247-1248.
63. Tuncer H.H., Rana N., Milani C., et al. Gastrointestinal and hepatic complications ofhematopoietic stem cell transplantation. World J Gastroenterol 2012, 18:1851-1860.
64. Pai R.K., van Besien K., Hart J., et al. Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant. Leuk Lymphoma 2012, 53:1552-1557.
65. Gao H., Li N., Wang J.Y., et al. Definitive diagnosis of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids. JDig Dis 2012, 13:33-39.
66. Larrey D., Faure S. Herbal medicine hepatotoxicity: a new step with development of specific biomarkers. JHepatol 2011, 54:599-601.
67. Corbacioglu S., Kernan N., Lehmann L., et al. Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. Expert Rev Hematol 2012, 5:291-302.
68. Platzbecker U., Bornhauser M. SOS for veno-occlusive disease: defibrotide prophylaxis. Lancet 2012, 379:1277-1278.
69. Richardson P.G., Corbacioglu S., Ho V.T., et al. Drug safety evaluation of defibrotide. Expert Opin Drug Saf 2013, 12:123-136.
70. van Erpecum K.J., Janssens A.R., Kreuning J., et al. Generalized peliosis hepatis and cirrhosis after long-term use of oral contraceptives. Am J Gastroenterol 1988, 83:572-575.
71. Neri M., Bello S., Bonsignore A., et al. Anabolic androgenic steroids abuse and liver toxicity. Mini Rev Med Chem 2011, 11:430-437.
72. Komori H., Beppu T., Baba Y., et al. Histological liver injury and surgical outcome after FOLFOX followed by a hepatectomy for colorectal liver metastases in Japanese patients. Int J Clin Oncol 2010, 15:263-270.
73. Gisbert J.P., Gonzalez-Lama Y., Mate J. Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review. Am J Gastroenterol 2007, 102:1518-1527.
74. Nam S.J., Cho J.Y., Lee H.S., et al. Chemotherapy-associated hepatopathy in Korean colorectal cancer liver metastasis patients: oxaliplatin-based chemotherapy and sinusoidal injury. Korean J Pathol 2012, 46:22-29.
75. Ryan P., Nanji S., Pollett A., et al. Chemotherapy-induced liver injury in metastatic colorectal cancer: semiquantitative histologic analysis of 334 resected liver specimens shows that vascular injury but not steatohepatitis is associated with preoperative chemotherapy. Am J Surg Pathol 2010, 34:784-791.
76. Agostini J., Benoist S., Seman M., et al. Identification of molecular pathways involved in oxaliplatin-associated sinusoidal dilatation. JHepatol 2012, 56:869-876.
77. Cazals-Hatem D., Hillaire S., Rudler M., et al. Obliterative portal venopathy: portal hypertension is not always present at diagnosis. JHepatol 2011, 54:455-461.
78. Schouten J.N., Garcia-Pagan J.C., Valla D.C., et al. Idiopathic noncirrhotic portal hypertension. Hepatology 2011, 54:1071-1081.
79. Krishnan P., Fiel M.I., Rosenkrantz A.B., et al. Hepatoportal sclerosis: CT and MRI appearance with histopathologic correlation. AJR Am J Roentgenol 2012, 198:370-376.
80. Mendizabal M., Craviotto S., Chen T., et al. Noncirrhotic portal hypertension: another cause of liver disease in HIV patients. Ann Hepatol 2009, 8:390-395.
81. Schiano T.D., Kotler D.P., Ferran E., et al. Hepatoportal sclerosis as a cause of noncirrhotic portal hypertension in patients with HIV. Am J Gastroenterol 2007, 102:2536-2540.
82. Lawal T.O., Farris A.B., El-Rayes B.F., et al. Oxaliplatin-induced hepatoportal sclerosis, portal hypertension, and variceal bleeding successfully treated with transjugular intrahepatic portosystemic shunt. Clin Colorectal Cancer 2012, 11:224-227.
83. Lopez-Martin C., de la Fuente-Fernandez E., Corbaton P., et al. Nodular regenerative hyperplasia: azathioprine-induced hepatotoxicity in a patient with Crohn's disease. Gastroenterol Hepatol 2011, 34:16-19.
84. Calabrese E., Hanauer S.B. Assessment of non-cirrhotic portal hypertension associated with thiopurine therapy in inflammatory bowel disease. JCrohns Colitis 2011, 5:48-53.
85. Vispo E., Moreno A., Maida I., et al. Noncirrhotic portal hypertension in HIV-infected patients: unique clinical and pathological findings. AIDS 2010, 24:1171-1176.
86. Schiano T.D., Uriel A., Dieterich D.T., et al. The development of hepatoportal sclerosis and portal hypertension due to didanosine use in HIV. Virchows Arch 2011, 458:231-235.
87. Jones M., Nunez M. Liver toxicity of antiretroviral drugs. Semin Liver Dis 2012, 32:167-176.
88. Jackson B.D., Doyle J.S., Hoy J.F., et al. Non-cirrhotic portal hypertension in HIV mono-infected patients. JGastroenterol Hepatol 2012, 27:1512-1519.
89. Lefkowitch J.H., Lobritto S.J., Brown R.S., et al. Ground-glass, polyglucosan-like hepatocellular inclusions: a "new" diagnostic entity. Gastroenterology 2006, 131:713-718.
90. Bua J., Marchetti F., Faleschini E., et al. Hepatic glycogenosis in an adolescent with diabetes. JPediatr 2010, 157:1042.
91. Torbenson M., Chen Y.Y., Brunt E., et al. Glycogenic hepatopathy: an underrecognized hepatic complication of diabetes mellitus. Am J Surg Pathol 2006, 30:508-513.
92. Carcione L., Lombardo F., Messina M.F., et al. Liver glycogenosis as early manifestation in type 1 diabetes mellitus. Diabetes Nutr Metab 2003, 16:182-184.
93. Abaci A., Bekem O., Unuvar T., et al. Hepatic glycogenosis: a rare cause of hepatomegaly in Type 1 diabetes mellitus. JDiabetes Complications 2008, 22:325-328.
94. Cuthbertson D.J., Brennan G., Walsh S., et al. Hepatic glycogenosis: abnormal liver function tests in Type 1 diabetes. Diabet Med 2007, 24:322-323.
95. Iancu T.C., Shiloh H., Dembo L. Hepatomegaly following short-term high-dose steroid therapy. JPediatr Gastroenterol Nutr 1986, 5:41-46.
96. Reasor M.J., Hastings K.L., Ulrich R.G. Drug-induced phospholipidosis: issues and future directions. Expert Opin Drug Saf 2006, 5:567-583.
97. Guigui B., Perrot S., Berry J.P., et al. Amiodarone-induced hepatic phospholipidosis: a morphological alteration independent of pseudoalcoholic liver disease. Hepatology 1988, 8:1063-1068.
98. Degott C., Messing B., Moreau D., et al. Liver phospholipidosis induced by parenteral nutrition: histologic, histochemical, and ultrastructural investigations. Gastroenterology 1988, 95:183-191.
99. Obert L.A., Sobocinski G.P., Bobrowski W.F., et al. An immunohistochemical approach to differentiate hepatic lipidosis from hepatic phospholipidosis in rats. Toxicol Pathol 2007, 35:728-734.
100. Levine P.H., Delgado Y., Theise N.D., et al. Stellate-cell lipidosis in liver biopsy specimens. Recognition and significance. Am J Clin Pathol 2003, 119:254-258.
101. Nollevaux M.C., Guiot Y., Horsmans Y., et al. Hypervitaminosis A-induced liver fibrosis: stellate cell activation and daily dose consumption. Liver Int 2006, 26:182-186.
102. Masia R., Pratt D.S., Misdraji J. Ahistopathologic pattern of centrilobular hepatocyte injury suggests 6-mercaptopurine-induced hepatotoxicity in patients with inflammatory bowel disease. Arch Pathol Lab Med 2012, 136:618-622.
103. Chang C.Y., Hernandez-Prera J.C., Roayaie S., et al. Changing epidemiology of hepatocellular adenoma in the United States: review of the literature. Int J Hepatol 2013, 2013:604860.
104. Deneve J.L., Pawlik T.M., Cunningham S., et al. Liver cell adenoma: a multicenter analysis of risk factors for rupture and malignancy. Ann Surg Oncol 2009, 16:640-648.
105. Socas L., Zumbado M., Perez-Luzardo O., et al. Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: a report of two cases and a review of the literature. Br J Sports Med 2005, 39:e27.
106. Martin N.M., Abu Dayyeh B.K., Chung R.T. Anabolic steroid abuse causing recurrent hepatic adenomas and hemorrhage. World J Gastroenterol 2008, 14:4573-4575.
107. Bork K., Schneiders V. Danazol-induced hepatocellular adenoma in patients with hereditary angio-oedema. JHepatol 2002, 36:707-709.
108. Lautz T.B., Finegold M.J., Chin A.C., et al. Giant hepatic adenoma with atypical features in a patient on oxcarbazepine therapy. JPediatr Surg 2008, 43:751-754.
109. Tazawa K., Yasuda M., Ohtani Y., et al. Multiple hepatocellular adenomas associated with long-term carbamazepine. Histopathology 1999, 35:92-94.
110. Cerminara C., Bagnolo V., De Leonardis F., et al. Hepatocellular adenoma associated with long-term exposure to phenobarbital: a paediatric case report. Childs Nerv Syst 2012, 28:939-941.
111. Defrance R., Zafrani E.S., Hannoun S., et al. Association of hepatocellular adenoma and focal nodular hyperplasia of the liver in a woman on oral contraceptives. Gastroenterol Clin Biol 1982, 6:949-950.
112. Hagay Z.J., Leiberman R.J., Katz M., et al. Oral contraceptives and focal nodular hyperplasia of the liver. Arch Gynecol Obstet 1988, 243:231-234.
113. Tajada M., Nerin J., Ruiz M.M., et al. Liver adenoma and focal nodular hyperplasia associated with oral contraceptives. Eur J Contracept Reprod Health Care 2001, 6:227-230.
114. Ikeda N., Oka K., Yonekawa N., et al. Pelioid-type well-differentiated hepatocellular carcinoma in a patient with a history of taking oral contraceptives: report of a case. Surg Today 2011, 41:1270-1274.
115. Singhal S., Jain S., Singla M., et al. Multifocal epitheloid hemangioendothelioma of liver after long-term oral contraceptive use-a case report and discussion of management difficulties encountered. JGastrointest Cancer 2009, 40:59-63.